Source: Virtual Congress 2020 – Asthma management: role of biomarkers and comorbidities
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Jovanovska Janeva (Skopje), D. Dokic (Skopje), G. Breskovska (Skopje), B. Kaeva (Skopje), Z. Goseva (Skopje), Z. Arsovski (Skopje), D. Trajkov (Skopje), O. Sibinovska (Skopje), M. Genadieva Dimitrova (Skopje). Evaluation of IL-17 and FEF25-75 in patients with uncontrolled moderate asthma. 1093

Member's Comments

No comment yet.

Related content which might interest you: Longitudinal modeling of prebronchodilator FEV1 response to benralizumab for patients with severe asthma Source: International Congress 2017 – Asthma management Year: 2017 Omalizumab significantly improves FEV1 in patients with severe persistent allergic asthma: a pooled analysis Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Salmeterol/fluticasone therapy improves FEV1 in mild and moderate more than in severe COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 342s Year: 2004 Follow-up of patients with severe asthma receiving reslizumab: an FEV1 analysis Source: International Congress 2017 – Asthma management Year: 2017 Evaluation of IL-8 and MEF25-75 in patients with severe COPD who were treated with combined therapy of ICSs / LABAs plus tiotropium bromide Source: Annual Congress 2013 –COPD: new markers of diseases Year: 2013 Patterns of bronchodilator reversibility of FEV1 in asthma and COPD patients Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 The FEF25-75/FVC ratio is related to exercise responsiveness in asthmatic children Source: Eur Respir J 2001; 18: Suppl. 33, 119s Year: 2001 Inflammatory cytokines in serum from children with severe asthma compared to controlled asthmatics Source: Annual Congress 2012 - Mechanisms and risk of childhood asthma and allergy Year: 2012 Raised FeNO is associated with lower FEV1 and FEV1/FVC in children with asthma Source: International Congress 2019 – Paediatric asthma: risk factors, biomarkers and the basics Year: 2019 Changes of TNF-a level in bronchoalveolar fluid of patients with chronic obstructive pulmonary disease before and after the 30 days treatment with tiotropium bromide Source: International Congress 2015 – Immunomodulation: basic science and clinical aspects Year: 2015 Response to bronchodilators in school children with asthma and normal FEV1 Source: International Congress 2016 – Living with asthma around the globe Year: 2016 Effect of tiotropium bromide on IFN-γ level: Results from 180-days study in moderate COPD patients with viral-induced exacerbations in anamnesis Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016 Reducing the decline of FEV1 after a 4-year therapy with montelukast in patients with bronchial asthma Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD Year: 2008 Changes in FEV1 and SpO2 in patients with severe and very severe COPD Source: Virtual Congress 2021 – Lung function testing in the management of obstructive diseases Year: 2021 Characteristics of asthmatic patients with a good vs poor correlation between clinical criteria of asthma control and expiratory flows Source: Eur Respir J 2003; 22: Suppl. 45, 536s Year: 2003 Treatment with corticosteroids and yearly decline of forced expiratory flow (FEV1) in patients with severe chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Respiratory structure and function Year: 2008 FEV1 decline and eosinophilia in occupational asthma Source: Annual Congress 2011 - The work environment in the clinic Year: 2011 Relationship between benralizumab exposure and asthma exacerbation rate for patients with severe asthma Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017 Increase in systemic IL-5 is associated with mepolizumab treatment failure in patients with severe asthma Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018